Back

Efficacy and safety with ticagrelor in patients with prior myocardial infarction in the approved european label: insights from PEGASUS-TIMI 54

28 August 2017 (08:30 - 12:30)
Organised by:
Congress Presentation Part of: Poster session 4 - Acute coronary syndromes Thrombosis and platelets ESC Premium Access ESC Congress 2017

About the speaker

Photo
Associate Professor Per Johanson

AstraZeneca R&D, Gothenburg (Sweden)

72 More presentations in this session

Presentation thumbnail
Professor S. Perlini (Pavia, IT)
Abstract
Presentation thumbnail
Doctor V. Bongard (Toulouse, FR)
Abstract
Presentation thumbnail
Doctor Y. Yang (Taoyuan, TW)
Abstract Slides
Presentation thumbnail
Doctor V. Kashtalap (Kemerovo, RU)
Abstract Slides
Presentation thumbnail
Mrs G. Veldre (Tartu, EE)
Abstract Slides

Access the full session

Session thumbnail
Poster session 4 - Acute coronary syndromes

The Event

Event poster

ESC Congress 2017

28 August 2017 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Comparative safety and effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndrome. An on treatment analysis from the multicenter CREA ARIAM Andalucia registry
19 March 2022
thumbnail
Congress Presentation
Infarct size following loading with ticagrelor/prasugrel versus clopidogrel in ST-segment elevation myocardial infarction
28 August 2020
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?
14 March 2025
thumbnail
Congress Presentation
Pleiotropic effects of ticagrelor on microRNA expression in acute coronary syndrome on long term follow up.
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources